Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Each participant must meet all the following inclusion criteria to be enrolled in the study:~1. Male or female participants ≥ 18 years old.~2. Have a pathologically (histology or cytology) confirmed diagnosis of SCLC.~3. Have received and progressed after a platinum-based standard chemotherapy regimen for first line treatment of SCLC, either limited stage (LS) or extensive stage (ES).~4. Have measurable disease within ≤ 2 weeks before randomization. Clear radiographic evidence of disease progression after initial therapy should have been documented.~5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (PS 0-1).~6. Participants with treated brain metastases (surgery, whole or stereotactic brain radiation) are allowed provided the lesions have been stable for at least 2 weeks and the participant is off steroids or is on a stable dose of steroids. Participants should be without neurologic dysfunction that would confound the evaluation of neurological and/or other AEs.~Exclusion Criteria~Participants meeting any of the following exclusion criteria are not to be randomized to treatment:~1. Any prior therapy for second-line treatment of SCLC.~2. Participants who relapsed ≥ 180 days after their response to first-line treatment.~3. Prior treatment with an Aurora A specific-targeted or pan-Aurora-targeted agent, including alisertib, or any other investigational agent.~4. Prior treatment with paclitaxel or any other taxane agent.~5. Known hypersensitivity to Cremophor® EL, paclitaxel, or its components.~6. Any comorbid condition or unresolved toxicity that would preclude administration of alisertib or weekly paclitaxel.~7. Prior history of ≥ Grade 2 neurotoxicity that is not resolved to ≤ Grade 1.~8. Participants with symptomatic and/or progressive brain metastases or with carcinomatous meningitis.~9. Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of alisertib and during study conduct. Major prohibited enzyme inducers include: phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, and St. John's wort.~10. Inability to swallow alisertib or other orally administered medications.~11. Requirement for administration of proton pump inhibitor (PPI), H2 antagonist, or pancreatic enzymes.~12. Diagnosed with or treated for another malignancy within 2 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease.~13. Other severe acute or chronic medical or psychiatric condition(s) per protocol.~14. History of myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, any ongoing cardiac arrhythmias of Grade \> 2, thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg, pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving the first dose of study drug.~15. Known history of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C.~16. Surgery within 3 weeks (or 2 weeks for a minor surgery) before study enrollment and not fully recovered to baseline or to a stable clinical status.~17. Participants who are pregnant, lactating, or do not agree to use effective methods of contraception during the study treatment period through 6 months after the last dose of study drug per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alisertib (MLN8237) + Paclitaxel (Type: EXPERIMENTAL): Alisertib 40 mg, tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 60 mg/m\^2 intravenously (IV) once a week for 3 weeks on Days 1, 8, and 15 in a 28-day until disease progression (Up to 17 Cycles).
- Placebo + Paclitaxel (Type: PLACEBO_COMPARATOR): Alisertib placebo-matching tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 80 mg/m\^2 IV once a week for 3 weeks on Days 1, 8, and 15 in a 28-day cycle until disease progression (Up to 22 Cycles).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete